SC144@HABN therapy combined with anti-PD-L1 antibody exerted robust anti-tumor efficacy and significantly decreased tumor growth, compared with SC144@HABN or SC144 + anti-PD-L1 therapy (p < 0.001 and p < 0.0001, respectively, Fig. 4b). Here, CD274 is linked to neoplasm.